185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

Abstract

Background: In patients (pts) with metastatic NSCLC without EGFR/ALK/ROS1 genomic aberrations, platinum doublet chemotherapy (ctx) + anti–PD-1/L1 immunotherapy is the current first-line standard of care. HER2 overexpression, an established target for treatments in breast and gastric cancers, is observed in up to 30% of pts with NSCLC. T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a membrane-permeable topoisomerase I inhibitor payload.